<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Flevari,P.</style></author><author><style face="normal" font="default" size="100%">Leftheriotis, D</style></author><author><style face="normal" font="default" size="100%">Kroupis, C.</style></author><author><style face="normal" font="default" size="100%">Antonakos, G.</style></author><author><style face="normal" font="default" size="100%">Lekakis, J.</style></author><author><style face="normal" font="default" size="100%">Dima, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Copeptin levels in patients with vasovagal syncope</style></title><secondary-title><style face="normal" font="default" size="100%">Int.J.Cardiol.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">Blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Electrocardiography</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Glycopeptides</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece</style></keyword><keyword><style  face="normal" font="default" size="100%">Heart Rate</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">physiology</style></keyword><keyword><style  face="normal" font="default" size="100%">physiopathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Plethysmography</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Precursors</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Syncope,Vasovagal</style></keyword><keyword><style  face="normal" font="default" size="100%">Tilt-Table Test</style></keyword><keyword><style  face="normal" font="default" size="100%">Vasoconstriction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017/03/01/</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">PM:28073658</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">230</style></volume><pages><style face="normal" font="default" size="100%">642 - 645</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Vasovagal syncope (VVS) is linked to more than one pathophysiologic mechanisms. Copeptin, an emerging cardiovascular marker, is a surrogate for arginine-vasopressin, which increases following VVS. We aimed to assess the dynamic pattern of copeptin levels in typical VVS, categorized by the degree of vasoconstriction during orthostasis, and healthy controls. METHODS: The following groups were studied: Group A (n=21), with adequate limb vasoconstriction during the first min. of tilt, assessed by limb plethysmography (at least 30% flow reduction); Group B (n=15), showing impaired vasoconstriction during orthostasis (&lt;10% reduction); Group C (n=18), history of VVS and negative tilt test result; Group D (n=18), healthy controls. Copeptin plasma levels were assessed before and 5min following tilt test positivity or termination. RESULTS: Baseline copeptin values were similar in all groups (8.3+/-6.4 in Group A, 5.7+/-2.3pmol/l in B, 6.0+/-1.9 in C, and 6.9+/-2.6 in D, p: 0.41). Significant increases in copeptin during tilt were observed in all Groups of VVS patients (A, B, C), including those with negative tilt (Group C: from 6.0+/-1.9 to 27.7+/-12.6pmol/l, p: 0.001), but not in controls. Following tilt termination, a greater increase was observed in copeptin values in Group B vs all other Groups A, C, and D (111.6+/-63.5 vs 29.5+/-51.3, 27.7+/-12.6, and 8.3+/-2.9, respectively). CONCLUSIONS: Copeptin increases following tilt not only in VVS with a positive response, but also in typical history patients with a negative test. Increased copeptin levels following orthostasis may be useful for diagnosing VVS</style></abstract><notes><style face="normal" font="default" size="100%">IS - 1874-1754 (Electronic)IS - 0167-5273 (Linking)LA - engPT - Journal ArticleRN - 0 (Biomarkers)RN - 0 (Glycopeptides)RN - 0 (Protein Precursors)RN - 0 (copeptins)SB - IM</style></notes></record></records></xml>